Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
Paula RackoffDivision of Rheumatology, Beth Israel Medical Center, New York, NY, USAAbstract: Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, howev...
Guardado en:
Autor principal: | Paula Rackoff |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2e882e93e2ed4f66b1cbb41c040349be |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
por: Tahir Masud, et al.
Publicado: (2009) -
Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
por: María J Moro-Álvarez, et al.
Publicado: (2008) -
The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil
por: Baccaro LF, et al.
Publicado: (2015) -
Comparison of OSTA, FRAX and BMI for Predicting Postmenopausal Osteoporosis in a Han Population in Beijing: A Cross Sectional Study
por: Fan Z, et al.
Publicado: (2020) -
LncRNA CASC11 is upregulated in postmenopausal osteoporosis and is correlated with TNF-α
por: Yu H, et al.
Publicado: (2019)